| Medical and Health Sciences | Lifetime | 392 | GB 45 | 99.98 |
| Medical and Health Sciences | 2021-2025 | 867 | GB 85 | 99.80 |
| Philosophy, Ethics and Religion | 2021-2025 | 554 | GB 76 | 88.77 |
| Psychiatry and Mental health | Lifetime | 27 | GB 4 | 99.92 |
| Clinical Neurology | Lifetime | 140 | GB 25 | 99.48 |
| Medical Physiology | Lifetime | 374 | GB 42 | 99.38 |
| General Health Professions | Lifetime | 982 | GB 151 | 98.87 |
| Clinical Pharmacology | Lifetime | 322 | GB 36 | 98.67 |
| Neuroscience of Neurology | Lifetime | 284 | GB 18 | 97.82 |
| Philosophy of Mind, Language and Cognitive Science | Lifetime | 193 | GB 38 | 97.60 |
| Complementary and Alternative Medicine | Lifetime | 424 | GB 38 | 97.51 |
| Geriatrics and Gerontology | Lifetime | 367 | GB 40 | 89.74 |
| Psychiatry and Mental health | 2021-2025 | 63 | GB 9 | 99.13 |
| Medical Physiology | 2021-2025 | 251 | GB 31 | 96.62 |
| Clinical Neurology | 2021-2025 | 268 | GB 29 | 92.19 |
| Philosophy of Mind, Language and Cognitive Science | 2021-2025 | 83 | GB 11 | 89.02 |
| Dementia and Cognitive Impairment Research | Lifetime | 20 | GB 4 | 99.93 |
| Neuroprotection in Stroke and Neurodegeneration | Lifetime | 11 | GB 3 | 99.78 |
| Cholinesterase and Neurodegenerative Diseases | Lifetime | 22 | GB 2 | 99.69 |
| Alzheimer's disease research and treatments | Lifetime | 70 | GB 8 | 99.79 |
| Neurological Disease Mechanisms and Treatments | Lifetime | 31 | GB 6 | 99.73 |
| Ginkgo biloba and Cashew Applications | Lifetime | 7 | GB 4 | 99.54 |
| Geriatric Care and Nursing Homes | Lifetime | 41 | GB 10 | 99.42 |
| Parkinson's Disease Mechanisms and Treatments | Lifetime | 106 | GB 21 | 99.57 |
| Schizophrenia research and treatment | Lifetime | 170 | GB 31 | 99.33 |
| Aging, Elder Care, and Social Issues | Lifetime | 226 | GB 41 | 95.28 |
| Medicinal Plants and Neuroprotection | Lifetime | 69 | GB 8 | 97.89 |
| Health Systems, Economic Evaluations, Quality of Life | Lifetime | 652 | GB 108 | 98.49 |
| Pharmaceutical Practices and Patient Outcomes | Lifetime | 236 | GB 26 | 97.81 |
| Computational Drug Discovery Methods | Lifetime | 474 | GB 35 | 97.91 |
| Cerebrovascular and genetic disorders | Lifetime | 40 | GB 7 | 97.91 |
| Psychiatric care and mental health services | Lifetime | 113 | GB 30 | 97.95 |
| Intensive Care Unit Cognitive Disorders | Lifetime | 494 | GB 30 | 97.56 |
| Neuromodulation and Treatments for Neurological Disorders | Lifetime | 765 | GB 68 | 97.11 |
| Healthcare Decision-Making and Restraints | Lifetime | 200 | GB 29 | 95.82 |
| Mental Health and Psychiatry | Lifetime | 384 | GB 74 | 97.17 |
| Family Caregiving in Mental Illness | Lifetime | 167 | GB 34 | 96.07 |
| Cardiovascular Syncope and Autonomic Disorders | Lifetime | 551 | GB 39 | 95.30 |
| Medicinal Plant Extracts Effects | Lifetime | 51 | GB 9 | 93.21 |
| Intergenerational Family Dynamics and Caregiving | Lifetime | 558 | GB 67 | 94.46 |
| Pain Management and Opioid Use | Lifetime | 981 | GB 67 | 92.07 |
| Hallucinations in medical conditions | Lifetime | 53 | GB 19 | 90.55 |
| Down syndrome and intellectual disability research | Lifetime | 347 | GB 75 | 89.00 |
| Cognitive Functions and Memory | Lifetime | 717 | GB 60 | 79.13 |
| Dementia and Cognitive Impairment Research | 2021-2025 | 99 | GB 7 | 98.96 |
| Alzheimer's disease research and treatments | 2021-2025 | 190 | GB 12 | 97.89 |
| Schizophrenia research and treatment | 2021-2025 | 270 | GB 46 | 94.85 |
| Parkinson's Disease Mechanisms and Treatments | 2021-2025 | 731 | GB 56 | 92.40 |
| Geriatric Care and Nursing Homes | 2021-2025 | 539 | GB 68 | 89.96 |
| Cholinesterase and Neurodegenerative Diseases | 2021-2025 | 360 | GB 3 | 84.06 |
| Aging and Gerontology Research | 2021-2025 | 237 | GB 10 | 85.68 |
| Neurological Disease Mechanisms and Treatments | 2021-2025 | 878 | GB 35 | 73.24 |
| Psychiatric care and mental health services | 2021-2025 | 536 | GB 112 | 61.99 |
| Healthcare Decision-Making and Restraints | 2021-2025 | 941 | GB 136 | 55.32 |
